Clinical trials: 5-Fluorouracil
Recurrent Colon Cancer, Recurrent Rectal Cancer
Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy
This pilot clinical trial studies short-infusion ziv-aflibercept in treating patients with metastatic colorectal cancer receiving combination chemotherapy.
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer
- Trial name
- NCT01941173
- Testing
- ziv-aflibercept, leucovorin calcium, irinotecan hydrochloride
- Where
- 3 sites in United States
- Sponsor
- City of Hope Medical Center
Adenocarcinoma of the Rectum, Mucinous Adenocarcinoma of the Colon
Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer
Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Adenocarcinoma of the Rectum, Mucinous Adenocarcinoma of the Colon, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00100841
- Testing
- cetuximab, bevacizumab, oxaliplatin
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Rectal Cancer
Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer
The treatment protocol proposed in this study is to perform short-term radiation therapy and 4 cycles of FOLFOX chemotherapy for neoadjuvant treatment of locally advanced rectal cancer.
- Trial name
- SOLAR (NCT05673772)
- Testing
- short-course radiotherapy, mFOLFOX6, Chemoradiotherapy
- Where
- 9 sites in South Korea
- Volunteers
- 364 people
- Sponsor
- Kyungpook National University Hospital
High-Risk Non-Muscle Invasive Bladder Cancer
A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer.
In the UK 20,000 people develop urothelial bladder cancer each year with 75-80% having Non-Muscle Invasive Bladder Cancer (NMIBC).
- Trial name
- TRAIN (NCT07268339)
- Testing
- radiotherapy, BCG
- Where
- United Kingdom
- Volunteers
- 328 people
- Sponsor
- The Christie NHS Foundation Trust
Pancreas Cancer
Biomarker Directed Adjuvant Chemotherapy for Resected Pancreas Cancer
Chemotherapy is given after curative surgery for pancreas cancer to try to improve cure rates. There are two choices of chemotherapy which are currently considered equal treatments: gemcitabine or 5-fluorouracil (5FU).
- Trial name
- NCT01411072
- Testing
- gemcitabine, 5-fluorouracil
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- AHS Cancer Control Alberta
Colorectal Cancer, Metastatic Colorectal Cancer
Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer
This is an open-label Phase 2 study to evaluate the safety and efficacy of Tovecimig combined with FOLFIRI in patients who have received one prior line of therapy for advanced or metastatic colorectal cancer (CRC).
- Trial name
- NCT07662031
- Testing
- Tovecimig, Irinotecan, Leucovorin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Washington University School of Medicine
Cancer of Pancreas
Induction Chemotherapy, FOLFIRINOX Followed With Concurrent Capecitabine and Radiation Therapy in Inoperable Locally Advanced Cancer of the Pancreas
This prospective cohort, phase II, trial is studying induction chemotherapy combination, FOLFIRINOX regimen, consisted of oxaliplatin, irinotecan, leucovorin and fluorouracil (5-FU), for 4 cycles, followed by consolidation…
- Trial name
- NCT02311439
- Testing
- FOLFIRINOX + CRT
- Where
- Egypt
- Volunteers
- 1 people
- Sponsor
- Assiut University
Rectal Cancer
Cetuximab (Erbitux®), Capecitabine and Radiotherapy in Neoadjuvant Treatment of Patients With Rectal Cancer
This is a nonrandomised pilot trial to establish the role of intravenous cetuximab when added to a schedule of capecitabine plus pelvic radiation in patients who have locally advanced primary resectable rectal cancers.
- Trial name
- XERT (NCT00689702)
- Testing
- cetuximab, capecitabine
- Where
- Slovenia
- Volunteers
- 43 people
- Sponsor
- Institute of Oncology Ljubljana
Rectal Cancer
RP II Study of SOX vs mFOLFOX6 in Patients With Resectable Rectal Cancer (KSCC1301).
To evaluate the efficacy and safety of SOX or mFOLFOX6 as neoadjuvant chemotherapy in patients with resectable rectal cancer, and to identify the more promising regimen.
- Trial name
- NCT02280070
- Testing
- Laboratory test, Medical history and physical examination, BW and height
- Where
- 2 sites in Japan
- Volunteers
- 110 people
- Sponsor
- Clinical Research Support Center Kyush
CRC, Metastatic Colorectal Cancer
Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC
The aim of this study is to evaluate the efficacy and safety of short course radiotherapy followed by fruquintinib combined with Sintilimab as the first-line treatment of advanced mCRC compared to bevacizumab combined with…
- Conditions
- CRC, Metastatic Colorectal Cancer, Metastatic Colorectal Adenocarcinoma
- Trial name
- NCT06195670
- Testing
- Experimental, Active Comparator
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Zhejiang Cancer Hospital
Colorectal Cancer
Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD)
Surgery is the main treatment method for colon cancer. About 50% of patients can be cured with surgery alone. For colon cancer with high-risk stage II or III after surgery, the current guidelines recommend 3-6 months after…
- Trial name
- AFFORD (NCT05427669)
- Testing
- mFOLFOXIRI, mFOLFOX6
- Volunteers
- 340 people
- Sponsor
- Yanhong Deng
Metastatic Colorectal Cancer With Left-sided Primary Tumor, Immunotherapy
Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC
This is a two-arm, randomized phase II clinical study. It is planned to enroll 44 patients with primary left-sided, RAS and BRAF wild-type metastatic colorectal cancer.
- Trial name
- NCT07070713
- Testing
- FOLFOXIRI + QL1706 + Bevacizumab, FOLFOX+QL1706+Cetuximab
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Fujian Cancer Hospital
Stomach Neoplasms, Esophageal Neoplasms
Safety and Efficacy of G17DT Immunogen in the Treatment of Gastric and Gastroesophageal Cancer
This study will test whether the G17DT Immunogen, when administered in combination with chemotherapy, is an effective and safe treatment for gastric cancer.
- Trial name
- NCT00042510
- Testing
- Treatment group
- Volunteers
- 103 people
- Sponsor
- Cancer Advances Inc.
HER2-negative Breast Cancer, Advanced Breast Cancer
Organoid-based Functional Precision Therapy for Advanced Breast Cancer
This is a phase II, multicenter, open-label, randomized controlled trial to compare the efficacy of organoid-guided treatment (OGT) to treatment of physician's choice (TPC) in previously treated, HER2-negative locally advanced or…
- Trial name
- ORIENTA (NCT06102824)
- Testing
- Organoid-guided treatment, Taxane, Capecitabine
- Where
- China
- Volunteers
- 252 people
- Sponsor
- Guangdong Provincial People's Hospital
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
The purpose of this study is to evaluate the safety, tolerability and maximum tolerated dose of tislelizumab in combination with pamiparib plus chemoradiotherapy (chemotherapy and radiation) in individuals with recurrent head and…
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Head and Neck Cancer Stage IV
- Trial name
- NCT05526924
- Testing
- Chemoradiation, Pamiparib, Hydroxyurea
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Chicago
Advanced Malignant Tumors
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK112 (anti-PD-1 and VEGF bispecific antibody) combined with AK117#AntiCD47 Antibody# in advanced malignant tumors
- Trial name
- NCT05229497
- Testing
- AK112, AK117, Carboplatin
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Akeso
Gastric Cancer
Multicentric Randomised Trial for Resectable Gastric Cancer
The CRITICS-II trial aims to identify the optimal preoperative regimen in resectable gastric cancer by comparing three investigational treatment arms: chemotherapy vs. chemotherapy and subsequent chemoradiotherapy vs.
- Trial name
- CRITICS-II (NCT02931890)
- Testing
- Docetaxel, Oxaliplatin, Capecitabine
- Where
- 28 sites in Netherlands
- Volunteers
- 207 people
- Sponsor
- The Netherlands Cancer Institute
HPV-Related Squamous Cell Carcinoma, HNSCC
Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer
Carboplatin, nab-paclitaxel, and nivolumab combination will be administered for three cycles of three weeks duration each. TORS or RT/CRT will be performed after induction chemotherapy (i.e. day 64 of therapy).
- Trial name
- OPTIMA-II (NCT03107182)
- Testing
- nab-paclitaxel, Carboplatin, Nivolumab
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Chicago
Locally Advanced Rectal Cancer
Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer.
The Efficacy and Safety of Long-Course Preoperative Chemoradiotherapy Combined with Consolidation or Induction NALIRIFOX Chemotherapy in the Treatment of Locally Advanced Rectal Cancer: A Prospective, Multicenter, Phase II Study.
- Trial name
- NCT06894797
- Testing
- Concurrent Chemoradiotherapy（Radiation + Capecitabine）, irinotecan hydrochloride liposome injection, Oxaliplatin
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Peking University Cancer Hospital & Institute
Breast Cancer
Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine and vinorelbine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00093808
- Testing
- trastuzumab, capecitabine, vinorelbine tartrate
- Where
- 147 sites in United States
- Volunteers
- 47 people
- Sponsor
- Alliance for Clinical Trials in Oncology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.